Q-omics provides the consensus-scored ELOVL7 profile across patient tissues and cancer cell-line models. ELOVL7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ELOVL7 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ELOVL7 RNA expression shows 18,539 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where ELOVL7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOVL7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOVL7 survival associations across molecular data types. ELOVL7 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOVL7 RNA expression–survival associations across cancer types. High ELOVL7 expression shows unfavorable associations in UCEC, UVM and LIHC, but favorable associations in KIRC, ACC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ELOVL7 RNA expression.
This table summarizes ELOVL7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ELOVL7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOVL7 shows higher tumor expression in KIRC, STAD, HNSC, KIRP, BLCA and LIHC. The KIRC box plot shows higher ELOVL7 RNA expression in tumor versus normal tissue (log2 FC = +0.798, t-test p < 0.001).
This table shows molecular features associated with ELOVL7 in patient tissues and cancer cell lines. In patient samples, ELOVL7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ELOVL7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
